1. Antitumor activity of AMG 102 in combination with bevacizumab or motesanib.
Antitumor activity of AMG 102 in combination with bevacizumab or motesanib. A, best result of 10 evaluable patients according to modified RECIST (bars). Four patients (breast cancer, colon cancer, bladder cancer, and unknown carcinoma) discontinued before postdose tumor assessment as a result of disease progression, adverse events, or serious adverse events. B, progression-free survival and diagnosis for 10 evaluable patients according to modified RECIST. Each bar is labeled by cohort number (1 = 3 mg/kg AMG 102 plus 10 mg/kg bevacizumab; 2 = 10 mg/kg AMG 102 plus 10 mg/kg bevacizumab; 3 = 20 mg/kg AMG 102 plus 10 mg/kg bevacizumab; 4 = 3 mg/kg AMG 102 plus 75 mg/day motesanib). *, patient had best response of progressive disease owing to the development of new lesions; all other patients had best response of stable disease. †, patients without progressive disease at the last disease assessment date were censored.
Peter J. Rosen et al. Clin Cancer Res 2010;16:
©2010 by American Association for Cancer Research